StocksMedium•5 November 2026•
1 min read
Agenus Reports Q3 Profit and Advances Phase 3 Colon Cancer Trial
Key Facts
1Agenus reported financial results for the third quarter ended September 30, 2026, achieving a profit.
2The company made progress in preparing the global Phase 3 ROBBIN trial for colon cancer treatment.
3Agenus received its first marketing authorizations for the BOT+BAL treatment combination.
Agenus reported financial results for the third quarter ended September 30, 2026, achieving a profit during the period. Investing.com reported that the company made progress in preparing the global Phase 3 ROBBIN trial for the treatment of colon cancer.
Agenus received its first marketing authorizations for the BOT+BAL treatment combination, marking a transition toward commercialization. These clinical and regulatory milestones coincide with the company reaching profitability while continuing to advance its late-stage oncology pipeline.